Bacteria in COPD; their potential role and treatment.

Translational respiratory medicine Pub Date : 2013-12-01 Epub Date: 2013-08-30 DOI:10.1186/2213-0802-1-13
Paul T King, Martin MacDonald, Philip G Bardin
{"title":"Bacteria in COPD; their potential role and treatment.","authors":"Paul T King, Martin MacDonald, Philip G Bardin","doi":"10.1186/2213-0802-1-13","DOIUrl":null,"url":null,"abstract":"<p><p>The role of bacterial infection in chronic obstructive pulmonary disease (COPD) and how it should be treated has been an ongoing source of controversy. For many years bacterial infection has not been thought to have an important effect in the pathology of this condition. Recent advances in diagnostic techniques, particularly the use 16S sequencing has demonstrated that there are a large range of bacteria present in the lower respiratory tract, both in terms of exacerbations and chronic colonization. A proportion of the bacteria present in the lower respiratory have also been shown to produce inflammation and hence are likely to be relevant for the pathogenesis of COPD. The accurate diagnosis of bacterial infection in individual patients remains a major challenge. The trials that have assessed the effect of antibiotics in COPD have generally been of low quality and have not been placebo controlled. Recent studies of macrolides for long-term treatment in COPD have found significantly reduced rates of exacerbations. Major challenges remain in accurately defining the potential role of bacteria in the inflammatory process and how best to optimize the use of antibiotics without the overuse of this limited resource. Alternative strategies to treat infection in COPD remain very limited. </p>","PeriodicalId":90074,"journal":{"name":"Translational respiratory medicine","volume":"1 1","pages":"13"},"PeriodicalIF":0.0000,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733427/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational respiratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/2213-0802-1-13","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2013/8/30 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The role of bacterial infection in chronic obstructive pulmonary disease (COPD) and how it should be treated has been an ongoing source of controversy. For many years bacterial infection has not been thought to have an important effect in the pathology of this condition. Recent advances in diagnostic techniques, particularly the use 16S sequencing has demonstrated that there are a large range of bacteria present in the lower respiratory tract, both in terms of exacerbations and chronic colonization. A proportion of the bacteria present in the lower respiratory have also been shown to produce inflammation and hence are likely to be relevant for the pathogenesis of COPD. The accurate diagnosis of bacterial infection in individual patients remains a major challenge. The trials that have assessed the effect of antibiotics in COPD have generally been of low quality and have not been placebo controlled. Recent studies of macrolides for long-term treatment in COPD have found significantly reduced rates of exacerbations. Major challenges remain in accurately defining the potential role of bacteria in the inflammatory process and how best to optimize the use of antibiotics without the overuse of this limited resource. Alternative strategies to treat infection in COPD remain very limited.

慢性阻塞性肺病中的细菌;其潜在作用和治疗方法。
细菌感染在慢性阻塞性肺病(COPD)中的作用以及如何治疗一直存在争议。多年来,人们一直认为细菌感染在慢性阻塞性肺病的病理过程中并无重要影响。最近诊断技术的进步,特别是 16S 测序技术的使用表明,下呼吸道中存在着大量细菌,包括加重和慢性定植的细菌。部分存在于下呼吸道的细菌还被证明会产生炎症,因此很可能与慢性阻塞性肺病的发病机制有关。准确诊断个体患者的细菌感染仍是一项重大挑战。评估抗生素对慢性阻塞性肺病疗效的试验通常质量不高,且未进行安慰剂对照。最近对大环内酯类药物用于慢性阻塞性肺病长期治疗的研究发现,病情恶化率明显降低。在准确界定细菌在炎症过程中的潜在作用以及如何在不过度使用抗生素这一有限资源的情况下优化抗生素的使用方面,仍然存在重大挑战。治疗慢性阻塞性肺病感染的替代策略仍然非常有限。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书